cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Biomea Fusion Inc
2 own
6 watching
Current Price
$9.53
$0.11
(1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
280.07M
52-Week High
52-Week High
14.2
52-Week Low
52-Week Low
2.84
Average Volume
Average Volume
0.06M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization280.07M
icon52-Week High14.2
icon52-Week Low2.84
iconAverage Volume0.06M
iconDividend Yield--
iconP/E Ratio--
What does the Biomea Fusion Inc do?
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective irreversible inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Read More
How much money does Biomea Fusion Inc make?
News & Events about Biomea Fusion Inc.
Globe Newswire
18days ago
BMF-219 is the first menin inhibitor to be clinically studied in patients with KRAS-mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC)A pan-KRAS inhibitor targeting multiple KRAS mutations (including G12C, G12D and G12R, among others) has ...
Globe Newswire
26days ago
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic ...
Globe Newswire
1month ago
COVALENT-111,now underway in the US, has completed Phase I and is currently enrolling type 2 diabetes patients in the Phase II randomized, placebo-controlled portion of the trialBMF-219, an orally available covalent menin inhibitor, is being evaluated for its potential to enable the proliferation, ...
Globe Newswire
1month ago
BMF-500, an investigational third generation covalent FLT3 inhibitor, demonstrated preclinically: Picomolar affinity to activating FLT3 mutations including FLT3-ITD and various tyrosine kinase domain (TKD) mutationsMulti-fold higher potency and increased cytotoxicity than commercially available non-...
Globe Newswire
2 months ago
REDWOOD CITY, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Biomea)(Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and ...
Frequently Asked Questions
Frequently Asked Questions
What is Biomea Fusion Inc share price today?
plus_minus_icon
Can Indians buy Biomea Fusion Inc shares?
plus_minus_icon
How can I buy Biomea Fusion Inc shares from India?
plus_minus_icon
Can Fractional shares of Biomea Fusion Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Biomea Fusion Inc stocks?
plus_minus_icon
What is today’s traded volume of Biomea Fusion Inc?
plus_minus_icon
What is today’s market capitalisation of Biomea Fusion Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Biomea Fusion Inc?
plus_minus_icon
What percentage is Biomea Fusion Inc down from its 52-Week High?
plus_minus_icon
What percentage is Biomea Fusion Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$9.53
$0.11
(1.17%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00